Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41353592
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
ANXA3 hypomethylation as a prognostic biomarker in hepatitis B virus-related
acute-on-chronic liver failure
#MMPMID41353592
Wang Z
; Lv H
; Luo P
; Wang J
; Wang N
; Zhu H
; Wei X
; Zhang Y
; Fan Y
; Cui C
; Liu H
; Wang K
Ann Med
2025[Dec]; 57
(1
): 2595332
PMID41353592
show ga
BACKGROUND: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)
is associated with a poor prognosis. This research aimed to characterize the
expression pattern and clinical value of Annexin A3 (ANXA3) in HBV-ACLF patients.
METHODS: First of all, ACLF-related datasets were downloaded from the Gene
Expression Omnibus (GEO) database to carry out bioinformatics analyses. RT-qPCR,
ELISA, and Methylight were used to measure ANXA3 gene expression and promoter
methylation levels. A validation cohort was leveraged to further validate the
results. RESULTS: Transcriptome analysis showed that ANXA3 was among the most
differentially expressed genes when comparing dead patients with HBV-ACLF to
those with survivors. The mRNA and serum levels of ANXA3 were elevated, and
methylation levels were decreased in HBV-ACLF patients. The PMR value of ANXA3 in
patients with HBV-ACLF was negatively correlated with inflammation-related
cytokines IL-6, TNF-?, and IL-1?, as well as quantitative clinical parameters
AST, TBIL, PT, INR, NEUT%, and MELD score, and positively correlated with PTA
(all p?
free
free
free
